Such an MSC-assisted targeting delivery of IFN-β to the tumor bed may be advantageous because the excessive toxicity associated with systemic administration at effective doses limits its use as a clinically viable therapeutic modality. The gene discussed is IFNB1; the disease is neoplasm.